MENU
+Compare
BIB
ETF ticker: NASDAQ
AS OF
Apr 3, 12:21 PM (EDT)
Price
$45.65
Change
-$1.61 (-3.41%)
Net Assets
51.03M

BIB stock forecast, quote, news & analysis

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®... Show more

Category: #Trading
BIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for BIB with price predictions
Apr 02, 2025

Momentum Indicator for BIB turns negative, indicating new downward trend

BIB saw its Momentum Indicator move below the 0 level on March 25, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned negative. In of the 90 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for BIB turned negative on February 26, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

BIB moved below its 50-day moving average on March 25, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BIB crossed bearishly below the 50-day moving average on March 13, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BIB entered a downward trend on April 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BIB's RSI Indicator exited the oversold zone, of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BIB advanced for three days, in of 332 cases, the price rose further within the following month. The odds of a continued upward trend are .

BIB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are AstraZeneca PLC (NASDAQ:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Intra-Cellular Therapies (NASDAQ:ITCI).

Industry description

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

Market Cap

The average market capitalization across the ProShares Ultra Nasdaq Biotechnology ETF is 6.66B. The market cap for tickers in the group ranges from 24.17M to 208.98B. AZN holds the highest valuation in this group at 208.98B. The lowest valued company is OVID at 24.17M.

High and low price notable news

The average weekly price growth across all stocks in the ProShares Ultra Nasdaq Biotechnology ETF was 40%. For the same ETF, the average monthly price growth was 50%, and the average quarterly price growth was 324%. LXRX experienced the highest price growth at 53%, while PCVX experienced the biggest fall at -51%.

Volume

The average weekly volume growth across all stocks in the ProShares Ultra Nasdaq Biotechnology ETF was 31%. For the same stocks of the ETF, the average monthly volume growth was -10% and the average quarterly volume growth was 123%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 76
Price Growth Rating: 71
SMR Rating: 88
Profit Risk Rating: 84
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
BIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Fundamentals
Details
Category
Trading--Leveraged Equity
Address
ProShares Trust7501 Wisconsin Avenue,Suite 1000Bethesda
Phone
N/A
Web
www.proshares.com